StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3051% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

Earnings

LENZ Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$3.38M
-72.9% on a year earlier
EPS, Q3 FY2026
-$0.99
-$0.59 a year earlier
Latest guidance
Issued
Oct 28, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of LENZ Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$3.38M-72.9%-$0.99Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours$5.50M+10.0%–Release
Q1 FY2026ended Mar 31, 2026May 11, 2026during market hours$1.90M–-$1.32Release
Q4 FY2025ended Dec 31, 2025Mar 24, 2026before the open$1.60M–-$1.16Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$12.50M–-$0.59Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025before the open$5.00M–-$0.53Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours––-$0.53Release
Q4 FY2024ended Dec 31, 2024Mar 19, 2025during market hours––-$0.46Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open––-$0.38Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024during market hours––-$0.40Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours––-$3.53Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

LENZ Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
one-time net restructuring chargesQ4 FY2026$5.00M–NewOct 28, 2026
operating expenses, excluding stock-based compensationnon-GAAPFY2027$70.00M – $75.00M–NewOct 28, 2026

Guidance history

Every forecast LENZ Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026one-time net restructuring chargesQ4 FY2026$5.00MNew
Oct 28, 2026operating expenses, excluding stock-based compensationFY2027$70.00M – $75.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases LENZ Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. News
  9. Results
  10. Results
  11. Results
  12. Results
  13. News
  14. Results
  15. News

See a number that looks wrong?